Astro-Med (NASDAQ: ALOT) reported Q4 EPS of $0.25, versus $0.10 reported last year. Revenue for the quarter came in at $32.7 million, versus $25.7 million reported last year.

Business Outlook

“As we begin fiscal 2019, we are optimistic about the year ahead and the long-term future of AstroNova,” continued Woods. “We are capitalizing on many product and business development initiatives, and we continue to see excellent growth opportunities from our TrojanLabel acquisition and our asset purchase and licensing agreement with Honeywell International\'s Aerospace division. In addition, as we seek to leverage our top-line growth into enhanced profitability, we see many ongoing operational excellence opportunities from the Honeywell and TrojanLabel integrations as well as through continued process improvements and automation that will enable us to further drive economies of scale.”

For earnings history and earnings-related data on Astro-Med (ALOT) click here.